EGFR and non-small cell lung carcinoma: Only one study from Korea has examined plasma metabolites in 15 NSCLC patients with and without EGFR mutation using liquid chromatography-mass spectrometry (LC-MS), identifying four potential biomarkers—linoleic acid, 5‐methyl-tetrahydrofolate, N‐succinyl‐L‐glutamate‐5-semialdehyde, and O-tetradecanoyl-L-carnitine — for EGFR mutation detection [19].